Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ASLN |
---|---|---|
09:32 ET | 1180 | 0.31 |
09:34 ET | 500 | 0.3112 |
09:43 ET | 200 | 0.310201 |
09:52 ET | 1258 | 0.31 |
09:57 ET | 200 | 0.3206 |
10:03 ET | 700 | 0.312749 |
10:10 ET | 453 | 0.3055 |
10:12 ET | 200 | 0.304 |
10:17 ET | 5100 | 0.309 |
10:21 ET | 2200 | 0.3055 |
10:24 ET | 800 | 0.3055 |
10:26 ET | 14839 | 0.3 |
10:28 ET | 6699 | 0.3 |
10:32 ET | 300 | 0.2999 |
10:44 ET | 5000 | 0.2979 |
10:46 ET | 4271 | 0.2979 |
10:48 ET | 1000 | 0.2953 |
10:50 ET | 2500 | 0.295 |
10:55 ET | 157 | 0.2979 |
11:00 ET | 1000 | 0.2964 |
11:04 ET | 200 | 0.2957 |
11:09 ET | 400 | 0.2957 |
11:18 ET | 100 | 0.2958 |
11:26 ET | 10200 | 0.295 |
11:27 ET | 600 | 0.2911 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aslan Pharmaceuticals Ltd | 6.9M | -0.1x | --- |
Transcode Therapeutics Inc | 6.9M | 0.0x | --- |
Virios Therapeutics Inc | 6.9M | -0.9x | --- |
Enzolytics Inc | 6.7M | 0.0x | --- |
NLS Pharmaceutics AG | 6.7M | -0.5x | --- |
Galera Therapeutics Inc | 7.2M | -0.1x | --- |
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.9M |
---|---|
Revenue (TTM) | $12.0M |
Shares Outstanding | 905.1K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.40 |
EPS | $-3.01 |
Book Value | $3.00 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -369.02% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.